Molbio Diagnostics, a leader in molecular diagnostics, has invested $30 million in OptraSCAN, a San Jose-based digital pathology innovator. This partnership aims to globally expand AI-powered diagnostic solutions and improve access to advanced healthcare technologies in underserved regions.

The collaboration focuses on cloud-based solutions for slide scanning, image analysis, and secure data storage. These tools are designed to enable faster, more precise diagnoses, enhancing patient care and supporting clinicians in diverse healthcare settings.

Sriram Natarajan, CEO of Molbio Diagnostics, emphasized the mission, stating, “Access to timely and accurate diagnostics should be a right, not a privilege. This partnership reflects our commitment to delivering affordable and innovative digital pathology solutions, empowering clinicians to provide better patient care across India and beyond.”

OptraSCAN plans to use this investment to expand its product range and increase access to diagnostic technology in rural and under-resourced areas. This collaboration will also fuel the development of AI-driven pathology tools, strengthening OptraSCAN’s R&D efforts and global presence. By merging resources, both companies aim to transform healthcare delivery and bring advanced diagnostics to regions with limited infrastructure.

Abhi Gholap, Founder and CEO of OptraSCAN, expressed enthusiasm about the alliance: “Partnering with Molbio enables us to bring life-saving digital pathology solutions to a broader audience. Together, we aim to bridge gaps in healthcare, ensuring laboratories of all sizes can deliver timely, precise diagnoses.”

This partnership marks a milestone in making high-quality, affordable diagnostics accessible globally, particularly in underserved communities.